Regenerx Overview

  • Year Founded
  • 1982

Year Founded

  • Status
  • Public

  • Employees
  • 8

Employees

  • Stock Symbol
  • RGRX

Stock Symbol

  • Investments
  • 1

Regenerx General Information

Description

Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.

Contact Information

Formerly Known As
Alpha 1 Biomedicals, Alpha 1 Biomedicals Inc
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 15245 Shady Grove Road
  • Suite 470
  • Rockville, MD 20850
  • United States
+1 (301)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 15245 Shady Grove Road
  • Suite 470
  • Rockville, MD 20850
  • United States
+1 (301)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Regenerx Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
457.00

Regenerx Financials Summary

As of 31-Mar-2023, Regenerx has a trailing 12-month revenue of $76.8K.

In Thousands,
USD
TTM 31-Mar-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 15,983 20,849 22,561 60,190
Revenue 77 77 77 77
EBITDA (1,363) (1,402) (1,273) (1,295)
Net Income (1,689) (1,727) (1,598) (1,523)
Total Assets 187 382 1,285 552
Total Debt 1,495 1,446 1,165 1,026
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Regenerx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Regenerx‘s full profile, request access.

Request a free trial

Regenerx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and
Drug Discovery
Rockville, MD
8 As of 2025

Vancouver, Canada
 

Geneva, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Regenerx Competitors (24)

One of Regenerx’s 24 competitors is viDA Therapeutics, a Venture Capital-Backed company based in Vancouver, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
viDA Therapeutics Venture Capital-Backed Vancouver, Canada
Light Chain Bioscience Formerly PE-Backed Geneva, Switzerland
Virometix Venture Capital-Backed Schlieren, Switzerland
Lisata Therapeutics Corporation Basking Ridge, NJ
Sangamo Therapeutics Formerly VC-backed Richmond, CA
You’re viewing 5 of 24 competitors. Get the full list »

Regenerx Patents

Regenerx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3177764-A1 Beta thymosin peptides for treating viral infections Pending 05-May-2020
EP-4146694-A2 Beta thymosin peptides for treating viral infections Inactive 05-May-2020
US-20230190878-A1 Beta thymosin peptides for treating viral infections Inactive 05-May-2020
WO-2021225960-A2 Beta thymosin peptides for treating viral infections Inactive 05-May-2020
WO-2021225960-A3 Beta thymosin peptides for treating viral infections Inactive 05-May-2020 A61K38/2292
To view Regenerx’s complete patent history, request access »

Regenerx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Regenerx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Regenerx‘s full profile, request access.

Request a free trial

Regenerx Investments (1)

Regenerx’s most recent deal was a Joint Venture with ReGenTree. The deal was made on 01-Jan-2015.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ReGenTree 01-Jan-2015 Joint Venture Drug Discovery
To view Regenerx’s complete investments history, request access »

Regenerx ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Regenerx’s complete esg history, request access »

Regenerx FAQs

  • When was Regenerx founded?

    Regenerx was founded in 1982.

  • Where is Regenerx headquartered?

    Regenerx is headquartered in Rockville, MD.

  • What is the size of Regenerx?

    Regenerx has 8 total employees.

  • What industry is Regenerx in?

    Regenerx’s primary industry is Drug Discovery.

  • Is Regenerx a private or public company?

    Regenerx is a Public company.

  • What is Regenerx’s stock symbol?

    The ticker symbol for Regenerx is RGRX.

  • What is Regenerx’s current revenue?

    The trailing twelve month revenue for Regenerx is $76.8K.

  • Who are Regenerx’s competitors?

    viDA Therapeutics, Light Chain Bioscience, Virometix, Lisata Therapeutics, and Sangamo Therapeutics are some of the 24 competitors of Regenerx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process